References
- Filby A, Taylor M. Smoking cessation interventions and services. York Health Economics Consortium. 2018; NICE Clinical Guidance 92. https://www.nice.org.uk/guidance/ng92/evidence/economic-modelling-report-pdf-4790596573. Accessed October 2018.
- Tran K, Asakawa K, Cimon K, Moulton K, Kaunelis D, Pipe A. Pharmacologic-Based Strategies for Smoking Cessation: Clinical and Cost-Effectiveness Analysis. Ottawa: Canadian Agency for Drugs and Technologies in Health; 2012.
- The United States Food and Drug Administration approved product label for varenecline: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/021928s045_046lbl.pdf. Accessed October 2018.
- Canadian Partnership Against Cancer (https://content.cancerview.ca/download/cv/prevention_and_screening/tobacco_cessation/documents/smoking_cessation_coverage_infographic_enpdf?attachment=0. Accessed October, 2018.
- Chaiton M, Diemert L, Cohen JE, et al. Estimating the number of quit attempts it takes to quit smoking successfully in a longitudinal cohort of smokers. BMJ Open. 2016;6(6):e011045.
- Stead LF, Koilpillai P, Fanshawe TR, Lancaster T. Combined pharmacotherapy and behavioural interventions for smoking cessation. Coch Database Syst Rev. 2016;3:CD008286.
- Gilbert H, Sutton S, Morris R, et al. Effectiveness of personalised risk information and taster sessions to increase the uptake of smoking cessation services (Start2quit): a randomised controlled trial. Lancet. 2017;389(10071):823–833.
- Crosbie PA, Balata H, Evison M, et al. Implementing lung cancer screening: baseline results from a community-based ‘lung health check’ pilot in deprived areas of Manchester. Thorax 2018; doi: 10.1136/thoraxjnl-2017-211377 [published Online First: 13 February 2018].